The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
TapImmune has amended the patient inclusion criteria for its Phase 2 clinical trial of the Company's T-cell therapeutic peptide vaccine TPIV200.
read more
Biohaven has commenced dosing of all 141 randomized patients with spinocerebellar ataxia in its Phase 2/3 trial of trigriluzole (previously known as ...
read more
Rebiotix has enrolled the first patient in a Phase 3 clinical trial of RBX2660 for the prevention of recurrent Clostridium difficile (C. diff) ...
read more
CMP Pharma announced the FDA has granted final approval of the company’s New Drug Application for CaroSpir.
read more
Eli Lilly and Company announced that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its ...
read more
AbbVie announced the FDA approved MAVYRET, a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus infection across all major...
read more
Thermo Fisher Scientific announced that the FDA has issued an Emergency Use Authorization for the company's new TaqPath Zika Virus Kit.
read more
Wednesday, August 02, 2017
Helsinn and MEI Pharma announced the first patient has been dosed in the Phase 3 study of pracinostat in combination with azacitidine in adults with ...
read more
Wednesday, August 02, 2017
Aprea Therapeutics announced the first patient was enrolled in a Phase Ib/II clinical study of APR-246 in platinum-resistant high-grade serous ovarian...
read more
Wednesday, August 02, 2017
The FDA has approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia who have a specific ...
read more
Pfizer reported financial results for second-quarter 2017, increased the midpoint of its 2017 financial guidance range for adjusted diluted EPS and ...
read more
AstraZeneca Pharmaceuticals, MedImmune LLC
AstraZeneca and MedImmune announced the FDA has granted Breakthrough Therapy Designation for Imfinzi for patients with locally-advanced, unresectable ...
read more
Amgen and Allergan announced the submission of a BLA to the FDA for ABP 980, a biosimilar candidate to Herceptin.
read more
Celltrion and Teva Pharmaceutical Industries announced the FDA has accepted for review the BLA for CT-P6, a proposed mAb biosimilar to Herceptin.
read more
Bristol-Myers Squibb and Clovis Oncology entered into a clinical collaboration agreement to evaluate the combination of immunotherapy Opdivo and poly ...
read more